by Acellular dermal matrices, commonly known as acellular cadaveric dermal matrices or acellular dermis matrices, are human tissue allografts derived from donated human skin tissue. These matrices help reduce contracture and provide support in soft tissue reconstructions like breast reconstruction surgeries.
The U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2783.32 million in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing usage of acellular dermal matrices in breast reconstruction surgeries is expected to drive the growth of U.S. acellular dermal matrices market over the forecast period. According to the American Society of Plastic Surgeons (ASPS), breast reconstruction using an implant was the most commonly performed reconstructive procedure in the United States and 166,448 breast reconstruction surgeries were performed in 2018. Acellular dermal matrices are widely used in breast reconstruction using tissue expanders and implants to prevent capsular contracture and provide lower pole coverage and support for breast implants. Thus, rising breast cancer rates and increasing number of breast reconstruction procedures performed is expected to boost the demand for acellular dermal matrices during the forecast period.
SWOT Analysis
Strength: U.S. Acellular Dermal Matrices have strong biocompatibility and reduce contraction when used in reconstruction surgeries. They help facilitate healing and integration with host tissue.
Weakness: Some matrices have high production costs and risk of infection transmission if not properly processed and sterilized before use.
Opportunity: Growing popularity of plastic and reconstructive surgeries for cosmetic enhancements and trauma/burn cases in the U.S. represents new opportunities.
Threats: Competitive pressure from alternative graft products and strict FDA regulations on matrix approval pose threats.
Key Takeaways
The U.S. Acellular Dermal Matrices Market Size is expected to witness high growth. The U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2783.32 million in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030.
Regional analysis related content comprises The Western region currently dominates the U.S. market due to high incidence of trauma cases and large base of specialty hospitals performing reconstructive surgeries. States like California and Texas with highly developed healthcare infrastructure contribute significantly to regional market value.
Key players related content comprises Key players operating in the U.S. Acellular Dermal Matrices market are Mylan, Integra Lifesciences, Globus Medical Inc, Stryker, Zimmer Biomet, Stratatech Corporation, Xtant Medical, and others. These leading companies are focused on developing advanced matrix technologies for specific clinical applications. They are also engaged in new product launches, facility expansion and partnerships to strengthen their market share.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
